Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares 0 3 Month Treasury Bond ETF (SGOV) vs Sanofi SA (SNY) Price & Performance

iShares 0 3 Month Treasury Bond ETFTrade

Price performance (Past 24H)

Key statistics

iShares 0 3 Month Treasury Bond ETF vs Sanofi SA — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.52, while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while iShares 0 3 Month Treasury Bond ETF pays none, and iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.

SGOVSNY
Sector
Fixed IncomeHealth
52-Week High
$100.74$52.34
52-Week Low
$100.28$41.33
Market Cap
$104.30B
Enterprise Value
$124.19B
Dividend Yield
5.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares 0 3 Month Treasury Bond ETF

SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.52, up 0.02% with a bearish technical signal from moving averages. It offers a defensive cash alternative, highlighted by recent institutional stake changes and a focus on ultra-short Treasury exposure amid market volatility. The ETF provides monthly distributions, with recent dividends around $0.30 per share.

The outlook remains stable as a low-risk income vehicle, benefiting from rising yields and investor defensive pivots. Key risks include interest rate fluctuations and macroeconomic shifts, but its principal protection and liquidity appeal to cautious investors seeking yield above traditional savings.

Sanofi SA

SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.

The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares 0 3 Month Treasury Bond ETF

SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.

Read more on SGOV

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY